| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 05/25/2000 | WO2000010595A3 Medicaments for manipulating t-cell immune response |
| 05/25/2000 | DE19850986A1 Die gentechnische Prägung von Zellen und ihre Verwendung zur Prophylaxe und Therapie von Erkrankungen The genetic imprint of cells and their use in the prophylaxis and treatment of diseases |
| 05/25/2000 | CA2351576A1 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| 05/25/2000 | CA2351224A1 Cox-2 inhibitors in combination with nmda-blockers for treating pain |
| 05/25/2000 | CA2351170A1 Humanized antibody specific for human 4-1bb and pharmaceutical composition comprising same |
| 05/25/2000 | CA2350785A1 31 human secreted proteins |
| 05/25/2000 | CA2350722A1 4-aroyl-piperidin-ccr-3 receptor antagonists iii |
| 05/25/2000 | CA2350531A1 Method for treating pain |
| 05/25/2000 | CA2350443A1 Fluorinated 3,4-dihydroquinoline derivatives used as nos inhibitors |
| 05/25/2000 | CA2350415A1 Inflammation-associated genes |
| 05/25/2000 | CA2349575A1 Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use |
| 05/25/2000 | CA2348824A1 12 human secreted proteins |
| 05/25/2000 | CA2348459A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 05/25/2000 | CA2347833A1 Antibody variants with higher binding affinity compared to parent antibodies |
| 05/24/2000 | EP1002545A1 Suppressive agent against expression of cell adhesion molecules |
| 05/24/2000 | EP1002531A1 A water-miscible composition of non-steroidal antiinflammatory drugs |
| 05/24/2000 | EP1002082A2 Transcriptional silencer protein nrf |
| 05/24/2000 | EP1002081A2 Delayed progression to aids by a missense allele of the ccr2 gene |
| 05/24/2000 | EP1002069A1 Peptides containing the motif igd and their use as cell migration modulators |
| 05/24/2000 | EP1001985A1 Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo |
| 05/24/2000 | EP1001979A1 Cyclic azapeptides with angiogenic effect |
| 05/24/2000 | EP1001975A1 Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001974A1 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001973A1 Compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001972A1 Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001971A1 Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001955A1 1,2,4-triazolo 4,3-b]pyrido 3,2-d]pyridazine derivatives and pharmaceutical compositions containing them |
| 05/24/2000 | EP1001946A1 QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56?1ck TYROSINE KINASES |
| 05/24/2000 | EP1001945A1 QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56?lck TYROSINE KINASES |
| 05/24/2000 | EP1001935A1 Indole derivatives as mcp-1 receptor antagonists |
| 05/24/2000 | EP1001934A1 Indole compounds as cox-2 inhibitors |
| 05/24/2000 | EP1001930A2 N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases |
| 05/24/2000 | EP1001805A1 Methods for identifying antibodies and peptides useful in the treatment of septic shock and experimental arthritis and uses thereof |
| 05/24/2000 | EP1001785A1 Use of colchinol derivatives as vascular damaging agents |
| 05/24/2000 | EP1001766A1 Compounds and methods |
| 05/24/2000 | EP1001759A2 Viral inhibition by long-chain alcohols, alkanes, fatty acids and amides |
| 05/24/2000 | EP1001757A1 Fast-acting analgesic |
| 05/24/2000 | EP1001755A2 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
| 05/24/2000 | EP1001753A1 Low dosed 15-desoxyspergualine preparations |
| 05/24/2000 | EP1001685A1 Nutritional composition containing methionine |
| 05/24/2000 | EP0787135B1 Water-soluble epipodophyllotoxin derivatives, preparation method therefor, and use thereof as a drug and for treating cancer |
| 05/24/2000 | CN1254344A Estrogenic 10-Noradnrost-17-one derivatives with aromatic B-ring |
| 05/24/2000 | CN1254341A Pharmaceutically accpetable salts of 3-hydroxy-estr-5-(10)-en-17-one 3-sulphate active as estrogens |
| 05/24/2000 | CN1254337A N-hydroxy 4-sulfonyl butyramide compounds |
| 05/24/2000 | CN1254335A Nicotinamide derivatives |
| 05/24/2000 | CN1254333A Immunotherapeutic imides/amides |
| 05/24/2000 | CN1253948A Substituted tricyclic compound |
| 05/24/2000 | CN1253833A Cell adhesion molecule expression inhibitor |
| 05/24/2000 | CN1253819A Chinese medicine for curing rheumatism and its application mehtod |
| 05/24/2000 | CN1253816A Capsule for curing chronic enteritis |
| 05/24/2000 | CN1253811A Ointment for curing rheumatic arthritis and its preparation method |
| 05/24/2000 | CN1253780A Method for extracting active component of sea cockroach |
| 05/24/2000 | CN1253775A Refractory vasculitis therapeutic preparation |
| 05/24/2000 | CN1052726C 7-azabicyclo-[2,2,1]-heptane and-heptene derivatives as analgesics and anti-inflammatory agents |
| 05/23/2000 | US6066730 Boronic ester and acid compounds, synthesis and uses |
| 05/23/2000 | US6066717 RsbW-1 protein |
| 05/23/2000 | US6066657 For the treatment of disease states associated with proteins which mediate cellular activity, for example by inhibiting tumor necrosis factor or phosphodiesterase iv |
| 05/23/2000 | US6066641 Phosphodiesterases as molecular targets for anti-asthmatic agents |
| 05/23/2000 | US6066633 Prevent tissue degradation |
| 05/23/2000 | US6066617 Polypeptide |
| 05/23/2000 | US6066502 Endothelin converting enzyme (ECE) |
| 05/23/2000 | US6066498 Compositions for the treatment and diagnosis of immune disorders |
| 05/23/2000 | US6066323 Use of antibodies to sialidase as anti-infectious agents and anti-inflammatory agents |
| 05/23/2000 | US6066322 Administering antibody to treat asthma; treating helper t-cell mediated conditions |
| 05/23/2000 | CA2171637C Substituted azaheterocyclecarboxylic acids |
| 05/18/2000 | WO2000028323A1 Methods for identifying modulators of bs69 activity |
| 05/18/2000 | WO2000028045A2 Human hydrolase proteins |
| 05/18/2000 | WO2000028039A2 Identification of senv genotypes |
| 05/18/2000 | WO2000028035A1 CHEMOKINE β-7 |
| 05/18/2000 | WO2000028022A1 Pge synthase and methods and means for modulating its activity |
| 05/18/2000 | WO2000028010A2 The genetic determination of genes and its use for the prophylaxis and therapy of diseases |
| 05/18/2000 | WO2000027870A1 Novel amino acid sequences, dna encoding the amino acid sequences, antibodies directed against such sequences and the different uses thereof |
| 05/18/2000 | WO2000027850A2 Crf receptor antagonists and methods relating thereto |
| 05/18/2000 | WO2000027842A1 Compounds |
| 05/18/2000 | WO2000027832A2 Thiazole derivatives as ppar gamma ligands |
| 05/18/2000 | WO2000027808A1 N-arylsulfonyl amino acid omega amides |
| 05/18/2000 | WO2000027802A1 Bicyclic signal transduction inhibitors, compositions containing them & uses thereof |
| 05/18/2000 | WO2000027432A1 USE OF AN ENTEROBACTERIUM PROTEIN OmpA FOR SPECIFIC TARGETING TOWARDS ANTIGEN-PRESENTING CELLS |
| 05/18/2000 | WO2000027422A2 Methods and compositions for treating or preventing peripheral neuropathies |
| 05/18/2000 | WO2000027414A2 Inhibition of the formation of vascular hyperpermeability |
| 05/18/2000 | WO2000027378A2 Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases |
| 05/18/2000 | WO2000027373A1 Dry powder pharmaceutical formulation |
| 05/18/2000 | WO2000027372A1 Pharmaceutical preparations for external use containing non-steroidal anti-inflammatory and analgesic agents |
| 05/18/2000 | WO2000027369A1 Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use |
| 05/18/2000 | WO2000027368A1 Particles coated with granulated crystalline ibuprofen |
| 05/18/2000 | WO2000027363A1 Aerosols comprising nanoparticle drugs |
| 05/18/2000 | WO2000027359A1 An inhalation system |
| 05/18/2000 | WO2000009130A3 New pharmaceutical uses for nos inhibitors |
| 05/18/2000 | WO2000008202A3 3-methylidenyl-2-indolinone modulators of protein kinase |
| 05/18/2000 | WO2000008141A3 Short oligonucleotides for the inhibition of vegf expression |
| 05/18/2000 | WO2000008140A3 Antisense oligonucleotides for the inhibition of vegf expression |
| 05/18/2000 | WO2000007544A3 Vitronectin receptor antagonists |
| 05/18/2000 | WO1999061467A3 Inhibition of the binding of protein tyrosine phosphatase pest to domains of signalling proteins |
| 05/18/2000 | WO1999058096A3 Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis |
| 05/18/2000 | DE19852508A1 Use of fat-soluble substance obtained from avocado oil as an antiphlogistic, antirheumatic, antimycotic or antiscabiotic agent, or as a toothpaste, lipstick, leather treatment agent or in bandages |
| 05/18/2000 | CA2351063A1 A system for administering a bioactive agent by inhalation comprising a lipid mixture comprising phosphatidylcholine |
| 05/18/2000 | CA2350771A1 Chemokine .beta.-7 |
| 05/18/2000 | CA2350388A1 Human hydrolase proteins |
| 05/18/2000 | CA2350183A1 Use of an enterobacterium protein ompa for specific targeting towards antigen-presenting cells |
| 05/18/2000 | CA2349904A1 Crf receptor antagonists and methods relating thereto |